Natera, Inc. NTRA | NASDAQ
Next Earnings: Aug 06, 2025
Company Overview:
5.7 Year NTRA Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
NTRA Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for NTRA
Based on past 5.7-year performance, here are NTRA growth metrics:
Share price CAGR of +28.68%
Dividend CAGR of +0%
Using NTRA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| NTRA (DRIP) | NTRA - No DRIP | |
|---|---|---|
| Current Price | $162.57 | $162.57 |
| Start Shares | 61.51 | 61.51 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 61.51 | 61.51 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $1,572.76 | $162.57 |
| Total Dividends | $0 | $0 |
| Final Value | $96,744 | $10,000 |
NOTE: Above numbers are our estimate based on NTRA's Dividend and Price CAGR over past 5.7 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Natera, Inc. (NTRA) had its IPO on 2015-07-01, and is trader on NASDAQ stock exchange.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
NTRA website: https://www.natera.com
